CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$2.42 USD
+0.12 (5.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.43 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth NA Momentum NA VGM
Balance Sheet
Fiscal Year End for CASI Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 31 | 51 | 49 | 66 | 54 |
Receivables | 10 | 13 | 10 | 5 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 6 | 2 | 1 | 5 |
Other Current Assets | 3 | 3 | 2 | 2 | 1 |
Total Current Assets | 59 | 73 | 62 | 74 | 62 |
Net Property & Equipment | 9 | 12 | 13 | 2 | 1 |
Investments & Advances | 2 | 7 | 40 | 29 | 14 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 1 | 12 | 13 | 17 |
Deposits & Other Assets | 1 | 1 | 2 | 0 | 1 |
Total Assets | 75 | 96 | 138 | 128 | 103 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 5 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 12 | 8 | 3 | 3 |
Income Taxes Payable | 0 | 2 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 17 | 13 | 8 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 3 | 2 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 19 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 12 | 14 | 14 | 1 |
Minority Interest (Liabilities) | 0 | 22 | 23 | 22 | 21 |
Total Liabilities | 51 | 52 | 54 | 46 | 30 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 1 | 1 | 1 |
Capital Surplus | 696 | 692 | 695 | 658 | 607 |
Retained Earnings | -661 | -637 | -606 | -571 | -524 |
Other Equity | -1 | -1 | 2 | 1 | -3 |
Treasury Stock | 10 | 9 | 8 | 8 | 8 |
Total Shareholder's Equity | 24 | 45 | 85 | 82 | 73 |
Total Liabilities & Shareholder's Equity | 75 | 96 | 138 | 128 | 103 |
Total Common Equity | 24 | 45 | 85 | 82 | 73 |
Shares Outstanding | 13.30 | 13.60 | 13.90 | 12.30 | 9.60 |
Book Value Per Share | 1.82 | 3.28 | 6.08 | 6.63 | 7.60 |
Fiscal Year End for CASI Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 31 | 36 | 39 | 44 |
Receivables | NA | 10 | 12 | 13 | 11 |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 16 | 9 | 8 | 9 |
Other Current Assets | NA | 3 | 2 | 2 | 3 |
Total Current Assets | NA | 59 | 58 | 61 | 67 |
Net Property & Equipment | NA | 9 | 10 | 10 | 11 |
Investments & Advances | NA | 2 | 4 | 4 | 7 |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | NA | NA |
Intangibles | NA | 2 | 0 | 1 | 1 |
Deposits & Other Assets | NA | 1 | 2 | 1 | 1 |
Total Assets | NA | 75 | 74 | 78 | 88 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 4 | 3 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | NA | NA | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 12 | 9 | 10 | 11 |
Income Taxes Payable | NA | 0 | NA | NA | 1 |
Other Current Liabilities | NA | 0 | NA | NA | NA |
Total Current Liabilities | NA | 17 | 12 | 12 | 14 |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | NA | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 19 | NA | NA | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | 12 | 12 | 12 | |
Minority Interest (Liabilities) | NA | 0 | 22 | 22 | 23 |
Total Liabilities | NA | 51 | 45 | 46 | 49 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 696 | 696 | 695 | 692 |
Retained Earnings | NA | -661 | -656 | -652 | -642 |
Other Equity | NA | -1 | -2 | -2 | -1 |
Treasury Stock | NA | 10 | 10 | 10 | 10 |
Total Shareholder's Equity | NA | 24 | 29 | 32 | 40 |
Total Liabilities & Shareholder's Equity | NA | 75 | 74 | 78 | 88 |
Total Common Equity | 0 | 24 | 100,028 | 100,031 | 100,039 |
Shares Outstanding | 13.40 | 13.30 | 13.30 | 13.30 | 13.30 |
Book Value Per Share | 0.00 | 1.82 | 7,520.89 | 7,521.15 | 7,521.70 |